<DOC>
	<DOCNO>NCT02102594</DOCNO>
	<brief_summary>The aim pilot study investigate application proteasome inhibitor Bortezomib ( Velcade® , approve therapy multiple myeloma ) patient therapy-refractory antibody-mediated autoimmune disease . The investigator hypothesis proteasome inhibition lead reduce antibody titer improve clinical outcome .</brief_summary>
	<brief_title>Therapy Antibody-mediated Autoimmune Diseases Bortezomib ( TAVAB )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>( main ) age 18 75 year screen ability give write consent , inform write consent negative pregnancy test screen therapyrefractory Myasthenia Gravis ( generalize ) Systemic Lupus Erythematosus Rheumatoid Arthritis ( main ) Belimumab therapy within last 6 month Bcelldepletion therapy within last 9 month heart kidney insufficiency know intolerability Bortezomib participation another interventional trial within last 3 month liver cirrhosis preexistent sensory motor polyneuropathy ≥ degree 2 ( NCI CTC AE criterion ) , within 14 day screen hint clinically apparent herpes zoster reactivation active systemic infection , viral infection ( CMV , EBV ) within last 6 month screen serologically active hepatitis B /or C , know HIV infection tumor disease currently within last 5 year clinically relevant liver , kidney bone marrow function disorder pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Myasthenia Gravis</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>proteasome inhibitor</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Velcade</keyword>
	<keyword>antibody-mediated autoimmune disease</keyword>
</DOC>